EX-99.1 2 ea0200177ex99-1_sapiens.htm PRESS RELEASE

Exhibit 99.1

 

 

Sapiens Reports Fourth Quarter 2023 Financial Results

 

February 20, 2024 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the fourth quarter ended December 31, 2023.

 

Summary Results for Fourth Quarter 2023 (USD in millions, except per share data)

 

   GAAP         Non-GAAP     
   Q4 2023   Q4 2022   % Change     Q4 2023   Q4 2022   % Change 
Revenue  $130.9   $119.5    9.5%    $130.9   $119.5    9.6%
Gross Profit  $55.9   $50.3    11.2%    $59.4   $53.8    10.4%
Gross Margin   42.8%   42.1%   70 bps      45.4%   45.0%   40 bps 
Operating Income  $20.1   $16.5    21.9%    $24.2   $21.1    14.7%
Operating Margin   15.4%   13.8%   160 bps      18.4%   17.6%   80 bps 
Net Income (*)  $17.0   $13.4    27.0%    $20.1   $18.0    11.4%
Diluted EPS  $0.30   $0.24    25.0%    $0.36   $0.32    12.5%

 

Summary Results for Full Year end 2023 (USD in millions, except per share data)

 

   GAAP        Non-GAAP    
   2023   2022   % Change     2023   2022   % Change 
Revenue  $514.6   $474.7    8.4%    $514.8   $474.8    8.4%
Gross Profit  $219.6   $200.2    9.7%    $233.0   $213.5    9.1%
Gross Margin   42.7%   42.2%   50 bps      45.3%   45.0%   30 bps 
Operating Income  $78.9   $66.5    18.6%    $94.1   $83.5    12.8%
Operating Margin   15.3%   14.0%   130 bps      18.3%   17.6%   70 bps 
Net income (*)  $62.4   $52.6    18.7%    $75.0   $67.2    11.7%
Diluted EPS  $1.12   $0.95    17.9%    $1.35   $1.21    11.6%

 

(*)Attributable to Sapiens’ shareholders

 

1

 

 

Roni Al-Dor, President and CEO of Sapiens, stated, “In 2023, Sapiens executed its growth strategy across our regions and product lines, achieving an 8.4% growth in non-GAAP revenue and bolstering non-GAAP operating profit by an impressive 12.8%. Our ARR in the fourth quarter was $164.8 million, a growth of 13.5% compared to the fourth quarter of 2022.

 

Our North American and European businesses have shown robust growth, and we are well-positioned to sustain growth in these markets in 2024. We completed multiple successful go-lives globally and demonstrated noteworthy expansion of our market share by signing about 30 new deals with both new and existing customers across core, Data, digital, and cloud in P&C, Workers’ Comp, Life, and Reinsurance. Furthermore, we anticipate continued momentum and growth with new logos and cross-selling opportunities within our existing accounts across all regions throughout 2024.”

 

“Key initiatives that will guide our strategic direction in 2024 include our continued transition to SaaS with all our products, with our evolved Sapiens Insurance Platform, an end-to-end integrated business-led SaaS platform with advanced technology and data capabilities,” continued Mr. Al-Dor. “In North America, EMEA, and APAC, we are increasing our headcount across sales, marketing, and product marketing to drive success. We remain focused on further expansion in North America, leveraging our investments in the region, and increasing our market share in Europe where we have a strong footprint.”

 

“We are introducing 2024 guidance for non-GAAP revenue in a range of $550 million to $555 million, and non-GAAP operating margin in a range of 18.1% to 18.5%,” concluded Mr. Al-Dor.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast on February 20, 2024, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): 1-888-642-5032

 

International: 972-3-9180609

 

UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

 

2

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, ARR, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

3

 

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Annual Recurring Revenue (“ARR”) as the annualized value of our revenue from customer subscriptions, term licenses, maintenance, application maintenance, and cloud solutions. The ARR run rate is equal to the product of (i) the sum of these revenues in our most recently completed fiscal quarter, multiplied by (ii) four.

 

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

4

 

 

About Sapiens

 

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative and agile. Backed by more than 40 years of industry expertise, Sapiens offers a complete insurance platform, with pre-integrated, low-code solutions and a cloud-first approach that accelerates customers’ digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers compensation and life markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management.  For more information visit www.sapiens.com or follow us on LinkedIn.

 

Investor and Media Contact

 

Yaffa Cohen-Ifrah
Chief Marketing Officer and Head of
Investor Relations, Sapiens
Yaffa.cohen-ifrah@sapiens.com
+1 917-533-4782  

Investors Contact Kimberly Rogers

 

Managing Director, Hayden IR
+1 541-904-5075
kim@HaydenIR.com

 

5

 

 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

6

 

  

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenue   130,859    119,463    514,584    474,736 
Cost of revenue   74,910    69,158    294,990    274,573 
                     
Gross profit   55,949    50,305    219,594    200,163 
                     
Operating expenses:                    
Research and development, net   16,084    15,251    63,475    58,656 
Selling, marketing, general and administrative   19,776    18,573    77,251    75,016 
Total operating expenses   35,860    33,824    140,726    133,672 
                     
Operating income   20,089    16,481    78,868    66,491 
                     
Financial and other expenses (income), net   (560)   (1,097)   1,750    941 
Taxes on income   3,624    4,276    14,251    12,619 
                     
Net income   17,025    13,302    62,867    52,931 
                     
Attributable to non-controlling interest   52    (65)   423    336 
                     
Net income attributable to Sapiens’ shareholders   16,973    13,367    62,444    52,595 
                     
Basic earnings per share   0.30    0.24    1.13    0.95 
                     
Diluted earnings per share   0.30    0.24    1.12    0.95 
                     
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   55,733    55,140    55,372    55,117 
                     
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   55,910    55,521    55,721    55,570 

 

7

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
GAAP revenue   130,859    119,463    514,584    474,736 
Valuation adjustment on acquired deferred revenue   55    23    220    92 
Non-GAAP revenue   130,914    119,486    514,804    474,828 
                     
GAAP gross profit   55,949    50,305    219,594    200,163 
Revenue adjustment   55    23    220    92 
Amortization of capitalized software   1,501    1,517    5,775    5,840 
Amortization of other intangible assets   1,865    1,929    7,396    7,375 
Non-GAAP gross profit   59,370    53,774    232,985    213,470 
                     
GAAP operating income   20,089    16,481    78,868    66,491 
Gross profit adjustments   3,421    3,469    13,391    13,307 
Capitalization of software development   (1,543)   (1,238)   (6,518)   (6,097)
Amortization of other intangible assets   1,169    1,115    4,403    4,783 
Stock-based compensation   698    759    3,658    3,960 
Acquisition-related costs (*)   318    472    339    1,033 
Non-GAAP operating income   24,152    21,058    94,141    83,477 
                     
GAAP net income attributable to Sapiens’ shareholders   16,973    13,367    62,444    52,595 
Operating income adjustments   4,063    4,577    15,273    16,986 
Taxes on income   (955)   78    (2,693)   (2,411)
Non-GAAP net income attributable to Sapiens’ shareholders   20,081    18,022    75,024    67,170 

 

(*)Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as tax, accounting and legal rendered until the acquisition date.

 

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
                 
GAAP operating profit   20,089    16,481    78,868    66,491 
                     
Non-GAAP adjustments:                    
Valuation adjustment on acquired deferred revenue   55    23    220    92 
Amortization of capitalized software   1,501    1,517    5,775    5,840 
Amortization of other intangible assets   3,034    3,044    11,799    12,158 
Capitalization of software development   (1,543)   (1,238)   (6,518)   (6,097)
Stock-based compensation   698    759    3,658    3,960 
Compensation related to acquisition and acquisition-related costs   318    472    339    1,033 
                     
Non-GAAP operating profit   24,152    21,058    94,141    83,477 
                     
Depreciation   1,115    1,034    3,865    4,242 
                     
Adjusted EBITDA   25,267    22,092    98,006    87,719 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q4 2023   Q3 2023   Q2 2023   Q1 2023   Q4 2022 
                     
Revenues   130,914    130,760    128,354    124,776    119,486 
Gross profit   59,370    59,260    57,992    56,363    53,774 
Operating income   24,152    24,058    23,417    22,514    21,058 
Adjusted EBITDA   25,267    24,777    24,393    23,569    22,092 
Net income to Sapiens’ shareholders   20,081    19,080    18,610    17,253    18,022 
                          
Diluted earnings per share   0.36    0.34    0.33    0.31    0.32 

 

9

 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q4 2023   Q3 2023   Q2 2023   Q1 2023   Q4 2022 
                     
North America   54,882    54,848    52,116    50,371    50,801 
Europe   65,239    64,662    62,960    64,572    56,910 
Rest of the World   10,793    11,250    13,278    9,833    11,775 
                          
Total   130,914    130,760    128,354    124,776    119,486 

 

Non-GAAP Revenue breakdown

U.S. dollars in thousands

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
                 
Software products and re-occurring post-production services (*)   90,399    77,702    342,156    300,241 
Pre-production implementation services (**)   40,515    41,784    172,648    174,587 
                     
Total Revenues   130,914    119,486    514,804    474,828 

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
                 
Software products and re-occurring post-production services (*)   48,815    42,120    182,154    161,534 
Pre-production implementation services (**)   10,555    11,654    50,831    51,936 
                     
Total Gross profit   59,370    53,774    232,985    213,470 

  

   Three months ended   Year ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
                 
Software products and re-occurring post-production services (*)   54.0%   54.2%   53.2%   53.8%
Pre-production implementation services (**)   26.1%   27.9%   29.4%   29.7%
                     
Gross Margin   45.4%   45.0%   45.3%   45.0%

 

(*) Software products and re-occurring post-production services include mainly subscription, term license, maintenance, application maintenance, cloud solutions and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

 

(**)Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

 

10

 

 

Annual Recurring Revenue (“ARR”)

U.S. dollars in thousands

 

  Three months ended 
  December 31, 
  2023   2022 
   164,840    145,188 

  

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

   Q4 2023   Q3 2023   Q2 2023   Q1 2023   Q4 2022 
                     
Cash-flow from operating activities   38,646    3,988    14,603    22,188    14,430 
Increase in capitalized software development costs   (1,543)   (1,638)   (1,679)   (1,658)   (1,238)
Capital expenditures   (421)   (696)   (775)   (634)   (400)
Free cash-flow   36,682    1,654    12,149    19,896    12,792 
                          
Cash payments attributed to acquisition-related costs(*) (**)   221    -    -    30    1,100 
                          
Adjusted free cash-flow   36,903    1,654    12,149    19,926    13,892 

 

(*)Included in cash-flow from operating activities

 

(**)Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

11

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

 

   December 31,   December 31, 
   2023   2022 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   126,716    160,285 
Short-term bank deposit   75,400    20,000 
Trade receivables, net and unbilled receivables   90,273    93,382 
Other receivables and prepaid expenses   22,514    11,640 
Total current assets   314,903    285,307 
           
LONG-TERM ASSETS          
Property and equipment, net   12,661    12,021 
Severance pay fund   3,605    3,996 
Goodwill and intangible assets, net   317,352    319,661 
Operating lease right-of-use assets   23,557    33,688 
Other long-term assets   17,546    13,671 
Total long-term assets   374,721    383,037 
           
TOTAL ASSETS   689,624    668,344 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   6,291    9,415 
Current maturities of Series B Debentures   19,796    19,796 
Accrued expenses and other liabilities   77,873    76,962 
Current maturities of operating lease liabilities   6,623    9,063 
Deferred revenue   38,541    30,720 
Total current liabilities   149,124    145,956 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   39,543    59,275 
Deferred tax liabilities   10,820    11,363 
Other long-term liabilities   11,538    13,312 
Long-term operating lease liabilities   21,084    28,432 
Redeemable non-controlling interest   -    89 
Accrued severance pay   7,568    7,063 
Total long-term liabilities   90,553    119,534 
           
EQUITY   449,947    402,854 
           
TOTAL LIABILITIES AND EQUITY   689,624    668,344 

 

12

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

   For the Twelve months ended
December 31,
 
   2023   2022 
   (unaudited)   (unaudited) 
Cash flows from operating activities:        
Net income   62,867    52,931 
Reconciliation of net income to net cash provided by operating activities:          
Depreciation and amortization   21,439    22,240 
Accretion of discount on Series B Debentures   64    85 
Capital loss from sale of property and equipment   195    26 
Stock-based compensation related to options issued to employees   3,658    3,960 
           
Net changes in operating assets and liabilities, net of amount acquired:          
Decrease (increase) in trade receivables, net and unbilled receivables   3,960    (21,860)
Decrease in deferred tax liabilities, net   (3,003)   (10,134)
Decrease (increase) in other operating assets   (5,402)   7,729 
Increase (decrease) in trade payables   (3,580)   4,634 
Decrease in other operating liabilities   (8,948)   (8,171)
Increase (decrease) in deferred revenues   7,266    (7,738)
Increase in accrued severance pay, net   909    78 
Net cash provided by operating activities   79,425    43,780 
           
Cash flows from investing activities:          
           
Purchase of property and equipment   (2,574)   (2,757)
Proceeds from (investments in) deposits   (55,499)   26 
Proceeds from sale of property and equipment   48    54 
Payments for business acquisitions, net of cash acquired   (8,060)   (3,466)
Capitalized software development costs   (6,518)   (6,097)
Acquisition of intellectual property   (177)   (200)
Net cash used in investing activities   (72,780)   (12,440)
           
Cash flows from financing activities:          
Proceeds from employee stock options exercised   4,809    - 
Distribution of dividend   (28,144)   (38,579)
Repayment of Series B Debenture   (19,796)   (19,796)
Acquisition of non-controlling interests   (161)   - 
Dividend to non-controlling interest   (47)   - 
Net cash used in financing activities   (43,339)   (58,375)
           
Effect of exchange rate changes on cash and cash equivalents   3,125    (2,923)
           
Decrease in cash and cash equivalents   (33,569)   (29,958)
Cash and cash equivalents at the beginning of period   160,285    190,243 
           
Cash and cash equivalents at the end of period   126,716    160,285 

 

13

 

  

Debentures Covenants

 

As of December 31, 2023, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding non-controlling interest): above $120 million.

 

Actual shareholders’ equity (excluding non-controlling interest) equal to $447.3 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.

 

Actual ratio of net financial indebtedness to net capitalization equal to (46.48)%.

 

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.

 

Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.46).

 

14